Wikisage, the free encyclopedia of the second generation, is digital heritage

Belzutifan: Difference between revisions

From Wikisage
Jump to navigation Jump to search
No edit summary
 
(10 intermediate revisions by the same user not shown)
Line 1: Line 1:
Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von Hippel-Lindau disease.
Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von [[Hippel-Lindau disease]].


Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α).
Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α).
Line 5: Line 5:
Belzutifan is the first drug to be awarded an "innovation passport" by the UK Medicines and Healthcare products Regulatory Agency (MHRA)<ref>https://en.wikipedia.org/wiki/Medicines_and_Healthcare_products_Regulatory_Agency</ref>
Belzutifan is the first drug to be awarded an "innovation passport" by the UK Medicines and Healthcare products Regulatory Agency (MHRA)<ref>https://en.wikipedia.org/wiki/Medicines_and_Healthcare_products_Regulatory_Agency</ref>


==ATC==
==[[ATC]]==
<gallery>File:Belzutifan.png</gallery>
 
none
{| style="background:Ivory; color:black" border=1 cellspacing=1 cellpadding=5
|colspan=2| <center>[[File:Belzutifan.png|92px]]
: [[wikipedia:belzutifan|belzutifan]] </center>
|}
[[File:Buecher_Regal_636.jpg|32px]]
Retinal angioma associated with cerebellar angioma and sometimes angioma in other organs<ref>Dictionary of Medical eponyms</ref>
 
==External links==
[https://www.karger.com/Article/FullText/431323 Ben-Skowronek I, Kozaczuk S] 2015: Von Hippel-Lindau Syndrome. Horm Res Paediatr 84:145-152. doi: 10.1159/000431323


{{wikidata|Q27456641}}
{{wikidata|Q27456641}}
{{refs}}
[[nl:Belzutifan]]

Latest revision as of 00:05, 14 August 2021

Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von Hippel-Lindau disease.

Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α).

Belzutifan is the first drug to be awarded an "innovation passport" by the UK Medicines and Healthcare products Regulatory Agency (MHRA)[1]

ATC

none

belzutifan

Retinal angioma associated with cerebellar angioma and sometimes angioma in other organs[2]

External links

Ben-Skowronek I, Kozaczuk S 2015: Von Hippel-Lindau Syndrome. Horm Res Paediatr 84:145-152. doi: 10.1159/000431323

Q27456641 at Wikidata  Interwiki via Wikidata


References

References: